查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949510

miRNA定序和檢測市場－全球產業規模、佔有率、趨勢、機會和預測（按技術、應用、最終用途、工作流程、地區和競爭格局分類，2021-2031年）

MiRNA Sequencing and Assay Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By End-use, By Workflow, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球微型RNA定序和檢測市場預計將從2025年的242.6億美元成長到2031年的355.6億美元，複合年成長率為6.58%。

這些基因組技術涉及檢測和定量小型非編碼RNA分子的方法，這些分子在基因表現調控中發揮關鍵作用。這一市場趨勢的主要驅動力是慢性疾病（包括癌症）的日益增多，這催生了對先進生物標記發現工具的強勁需求，這些工具對於早期診斷和患者分層至關重要。此外，精準醫療舉措的廣泛實施和基因組研究經費的不斷增加也為該領域的發展提供了重要動力。

市場概覽
預測期 2027-2031
市場規模：2025年 242.6億美元
市場規模：2031年 355.6億美元
複合年成長率：2026-2031年 6.58%
成長最快的細分市場 合成定定序
最大的市場 北美洲

儘管有這些正面趨勢，但該產業在分析通訊協定標準化方面仍面臨重大挑戰，導致不同平台間的資料可重複性難以保證。這種技術差異性嚴重阻礙了其在臨床上的廣泛應用和監管核准。美國癌症協會估計，到2024年，美國將新增約2,001,140例癌症病例，凸顯了此類診斷能力的重要性。因此，解決一致性問題對於滿足應對日益成長的癌症負擔的診斷需求至關重要。

市場促進因素

全球miRNA定序和檢測市場的成長主要受全球癌症和慢性疾病發生率上升的驅動，這促使人們需要能夠實現早期檢測和病患監測的非侵入性生物標記。由於miRNA在生物體液中穩定，因此它們在診斷流程中的應用日益廣泛，有助於改善臨床療效。世界衛生組織（WHO）下屬的國際癌症研究機構（IARC）也支持這項日益成長的需求。在2024年2月題為《全球癌症負擔日益加重》的新聞稿中，該機構預測到2050年，全球新增癌症病例將超過3500萬例，比2022年成長77%。這些預測凸顯了擴充性定序解決方案的必要性，以應對複雜疾病的大規模診斷篩檢。

同時，公共和私人對基因組研究的資金投入激增，加速了基於液態生物檢體的診斷技術的進步。這筆資金的湧入使生物技術公司能夠提高檢測的靈敏度並檢驗其臨床效用，從而有效降低了市場准入門檻。例如，Freenome在2024年2月發布的公告「Freenome融資2.54億美元推進早期癌症檢測」中宣布，資金籌措2.54億美元用於擴大篩檢平台的覆蓋範圍。此外，技術擴充性是此生態系的關鍵組成部分。 Illumina在2024年報告稱，其上一會計年度共交付了352台NovaSeq X測序儀，這表明該行業已具備堅實的基礎，能夠支持現代基因組檢測對高通量日益成長的需求。

市場挑戰

全球miRNA定序和檢測市場發展的主要障礙之一是缺乏標準化的分析通訊協定。不同的實驗室採用不同的工作流程、擷取方法和定序平台，常常導致數據不一致。這種技術差異使得結果的可重複性難以保證，而可重複性是臨床應用的基本要求，同時也阻礙了相關人員有效比較不同研究的結果。因此，醫療機構往往不願意將這些檢測方法應用於常規患者照護，阻礙了其廣泛應用。

這種碎片化也直接影響監管結果和商業性可行性，因為監管機構要求強力的分析有效性證據。數據不一致會顯著延緩新診斷工具的核准流程，並限制可靠檢測手段的可用性，進而影響現代治療方法。個人化醫療聯盟在2024年發布的數據凸顯了這個問題的迫切性，該聯盟預測，2023年核准的新藥中將有35%與個人化醫療相關。無法對這些治療方法的檢測方法進行標準化，限制了其收入潛力，並阻礙了整個微型RNA定序領域的擴張。

市場趨勢

將人工智慧融入miRNA生物標記發現領域，正從根本上重塑市場格局，使其能夠快速識別傳統分析方法往往忽略的複雜疾病特徵。先進的演算法如今可以處理海量多組體學資料集，並高精度地預測miRNA標靶，加速診斷試劑盒的開發。這項技術變革正得到各大運算公司的積極支持，他們提供了必要的基礎設施。例如，在2024年3月發布的題為「NVIDIA Healthcare發布生成式AI微服務，助力藥物研發、醫療技術和數位健康」的新聞稿中，NVIDIA推出了20多項新的微服務，用於在醫療機構部署生成式AI模型。這些工具能夠幫助研究人員有效地分析基因組數據，並顯著縮短檢驗潛在miRNA候選物用於臨床應用所需的時間。

同時，單細胞miRNA定序的日益普及正在推動市場擴張，因為它能夠解析細胞異質性，而這種異質性通常會被批量定序所掩蓋。這種精細化的方法在腫瘤學領域尤其重要，因為了解腫瘤微環境中不同細胞群的特異性miRNA譜對於開發標靶治療至關重要。製造商們正透過提供降低經濟門檻的低成本平台來支持這項變革。 10x Genomics在2024年10月的2024年第三季公佈財報上確認了其GEM-X Flex和Universal Multiplex Assays的出貨情況，這正體現了這一趨勢，使研究人員能夠以每個細胞不到1美分的成本分析數百萬個細胞。諸如此類的創新對於將單細胞分析從小眾學術研究領域推廣到更廣泛的臨床應用至關重要。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

5. 全球miRNA定序與檢測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術分類（合成定定序、寡核苷酸連接檢測 (SOLiD)、奈米孔定序、桑格定序、單分子即時 (SMRT)定序）
    • 依應用領域（癌症、麩胺酸紊亂、自體免疫疾病、思覺失調症等）
    • 按最終用途（製藥和生物技術行業、研究和學術機構、其他）
    • 按工作流程（樣品製備、定序、資料分析和儲存）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美miRNA定序與檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲miRNA定序與檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區miRNA定序與檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲 miRNA定序和檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲 miRNA定序與檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球miRNA定序與檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • PerkinElmer, Inc.
  • Abcam plc
  • New England Biolabs, Inc.
  • Takara Bio USA Inc.
  • Lexogen GmbH
  • Norgen Biotek Corp.
  • Maravai LifeSciences Holdings, Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 22109

The Global MiRNA Sequencing and Assay Market is projected to expand from USD 24.26 Billion in 2025 to USD 35.56 Billion by 2031, reflecting a CAGR of 6.58%. These genomic technologies encompass methods designed to detect and quantify small non-coding RNA molecules that play a crucial role in regulating gene expression. This market trajectory is primarily driven by the increasing prevalence of chronic conditions, particularly cancer, which creates a strong demand for advanced biomarker discovery tools essential for early diagnosis and patient stratification. Additionally, the broader implementation of precision medicine initiatives and increased funding for genomic research provide substantial momentum for the sector's growth.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 24.26 Billion
Market Size 2031USD 35.56 Billion
CAGR 2026-20316.58%
Fastest Growing SegmentSequencing By Synthesis
Largest MarketNorth America

Despite these favorable drivers, the industry faces significant hurdles regarding the standardization of analytical protocols, a factor that complicates data reproducibility across various platforms. This technical variability presents a major challenge to widespread clinical adoption and the acquisition of regulatory approval. The critical need for these diagnostic capabilities is highlighted by the American Cancer Society, which estimated that approximately 2,001,140 new cancer cases would occur in the United States in 2024. Consequently, resolving consistency issues is vital to meeting the urgent demand for diagnostics capable of addressing the rising cancer burden.

Market Driver

The growth of the Global MiRNA Sequencing and Assay Market is largely propelled by the rising global incidence of cancer and chronic diseases, which intensifies the need for non-invasive biomarkers facilitating early detection and patient monitoring. MiRNAs are increasingly utilized in diagnostic workflows due to their stability in biological fluids, helping to improve clinical outcomes. This escalating demand is underscored by the World Health Organization's International Agency for Research on Cancer; in a February 2024 press release titled 'Global cancer burden growing,' the agency predicted over 35 million new cancer cases in 2050, a 77% increase from 2022 levels. Such projections highlight the necessity for scalable sequencing solutions capable of managing high-volume diagnostic screening for complex pathologies.

Simultaneously, a surge in public and private funding for genomic research is accelerating the advancement of liquid biopsy-based diagnostics. This capital influx allows biotechnology firms to refine assay sensitivity and validate clinical utility, effectively reducing barriers to market entry. For instance, in a February 2024 announcement titled 'Freenome Raises $254 Million to Advance Early Cancer Detection,' Freenome reported securing $254 million to extend its screening platform's reach. Furthermore, technological scalability is a key component of this ecosystem, as evidenced by Illumina's 2024 report of shipping 352 NovaSeq X instruments during the prior fiscal year, indicating a robust industrial capacity to support the increasing throughput demands of modern genomic assays.

Market Challenge

A significant barrier to the progression of the global miRNA sequencing and assay market is the lack of standardized analytical protocols. Because laboratories employ varying workflows, extraction methods, and sequencing platforms, the resulting data frequently lacks consistency. This technical variability makes it difficult to reproduce results, which is a fundamental requirement for clinical acceptance, and prevents stakeholders from effectively comparing findings across different studies. Consequently, healthcare providers often hesitate to adopt these assays for routine patient care, stalling widespread integration.

This fragmentation also directly impacts regulatory outcomes and commercial viability, as regulatory bodies require robust evidence of analytical validity. Inconsistent data significantly delays the approval process for new diagnostic tools, restricting the availability of reliable tests needed to support modern therapeutic approaches. The urgency of this issue is highlighted by the Personalized Medicine Coalition, which reported in 2024 that personalized medicines accounted for 35 percent of all new drug approvals in 2023. The inability to standardize testing for such therapies limits revenue potential and hampers the overall expansion of the miRNA sequencing landscape.

Market Trends

The integration of artificial intelligence into miRNA biomarker discovery is fundamentally reshaping the market by facilitating the rapid identification of complex disease signatures that traditional analytical methods often miss. Advanced algorithms can now process extensive multi-omics datasets to predict miRNA targets with high precision, accelerating the development of diagnostic panels. This technological shift is actively supported by major computing firms providing the necessary infrastructure; for instance, in a March 2024 press release titled 'NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health,' NVIDIA introduced over two dozen new microservices to deploy generative AI models across healthcare enterprises. These tools enable researchers to efficiently analyze genomic data and significantly reduce the time required to validate potential miRNA candidates for clinical applications.

Concurrently, the increasing adoption of single-cell miRNA sequencing is driving market expansion by resolving the cellular heterogeneity that bulk sequencing often obscures. This granular approach is particularly vital in oncology, where understanding the specific miRNA profiles of distinct cell populations within a tumor microenvironment is essential for developing targeted therapies. Manufacturers are facilitating this shift by releasing cost-effective platforms that lower financial barriers; highlighting this trend, 10x Genomics confirmed in its October 2024 'Third Quarter 2024 Financial Results' announcement the shipping of its GEM-X Flex and Universal Multiplex assays, which enable researchers to run millions of cells for less than one cent per cell. Such innovations are critical for transitioning single-cell profiling from niche academic research to broader clinical utility.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • QIAGEN N.V.
  • PerkinElmer, Inc.
  • Abcam plc
  • New England Biolabs, Inc.
  • Takara Bio USA Inc.
  • Lexogen GmbH
  • Norgen Biotek Corp.
  • Maravai LifeSciences Holdings, Inc

Report Scope

In this report, the Global MiRNA Sequencing and Assay Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

MiRNA Sequencing and Assay Market, By Technology

  • Sequencing by Synthesis
  • Sequencing by Oligonucleotide Ligation and Detection (SOLiD)
  • Nanopore Sequencing
  • Sanger Sequencing
  • Single Molecule Real-time (SMRT) Sequencing

MiRNA Sequencing and Assay Market, By Application

  • Cancer
  • Polyglutamine Diseases
  • Autoimmune Disease
  • Schizophrenia
  • Others

MiRNA Sequencing and Assay Market, By End-use

  • Pharmaceutical & Biotechnology Industry
  • Research and Academic Institutes
  • Others

MiRNA Sequencing and Assay Market, By Workflow

  • Library Preparation
  • Sequencing
  • Data Analysis & Storage

MiRNA Sequencing and Assay Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global MiRNA Sequencing and Assay Market.

Available Customizations:

Global MiRNA Sequencing and Assay Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global MiRNA Sequencing and Assay Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Sequencing by Synthesis, Sequencing by Oligonucleotide Ligation and Detection (SOLiD), Nanopore Sequencing, Sanger Sequencing, Single Molecule Real-time (SMRT) Sequencing)
    • 5.2.2. By Application (Cancer, Polyglutamine Diseases, Autoimmune Disease, Schizophrenia, Others)
    • 5.2.3. By End-use (Pharmaceutical & Biotechnology Industry, Research and Academic Institutes, Others)
    • 5.2.4. By Workflow (Library Preparation, Sequencing, Data Analysis & Storage)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America MiRNA Sequencing and Assay Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By End-use
    • 6.2.4. By Workflow
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States MiRNA Sequencing and Assay Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-use
        • 6.3.1.2.4. By Workflow
    • 6.3.2. Canada MiRNA Sequencing and Assay Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-use
        • 6.3.2.2.4. By Workflow
    • 6.3.3. Mexico MiRNA Sequencing and Assay Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-use
        • 6.3.3.2.4. By Workflow

7. Europe MiRNA Sequencing and Assay Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By End-use
    • 7.2.4. By Workflow
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany MiRNA Sequencing and Assay Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-use
        • 7.3.1.2.4. By Workflow
    • 7.3.2. France MiRNA Sequencing and Assay Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-use
        • 7.3.2.2.4. By Workflow
    • 7.3.3. United Kingdom MiRNA Sequencing and Assay Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-use
        • 7.3.3.2.4. By Workflow
    • 7.3.4. Italy MiRNA Sequencing and Assay Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-use
        • 7.3.4.2.4. By Workflow
    • 7.3.5. Spain MiRNA Sequencing and Assay Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-use
        • 7.3.5.2.4. By Workflow

8. Asia Pacific MiRNA Sequencing and Assay Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By End-use
    • 8.2.4. By Workflow
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China MiRNA Sequencing and Assay Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-use
        • 8.3.1.2.4. By Workflow
    • 8.3.2. India MiRNA Sequencing and Assay Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-use
        • 8.3.2.2.4. By Workflow
    • 8.3.3. Japan MiRNA Sequencing and Assay Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-use
        • 8.3.3.2.4. By Workflow
    • 8.3.4. South Korea MiRNA Sequencing and Assay Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-use
        • 8.3.4.2.4. By Workflow
    • 8.3.5. Australia MiRNA Sequencing and Assay Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-use
        • 8.3.5.2.4. By Workflow

9. Middle East & Africa MiRNA Sequencing and Assay Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By End-use
    • 9.2.4. By Workflow
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia MiRNA Sequencing and Assay Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-use
        • 9.3.1.2.4. By Workflow
    • 9.3.2. UAE MiRNA Sequencing and Assay Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-use
        • 9.3.2.2.4. By Workflow
    • 9.3.3. South Africa MiRNA Sequencing and Assay Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-use
        • 9.3.3.2.4. By Workflow

10. South America MiRNA Sequencing and Assay Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By End-use
    • 10.2.4. By Workflow
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil MiRNA Sequencing and Assay Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-use
        • 10.3.1.2.4. By Workflow
    • 10.3.2. Colombia MiRNA Sequencing and Assay Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-use
        • 10.3.2.2.4. By Workflow
    • 10.3.3. Argentina MiRNA Sequencing and Assay Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-use
        • 10.3.3.2.4. By Workflow

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global MiRNA Sequencing and Assay Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Illumina, Inc.
  • 15.3. QIAGEN N.V.
  • 15.4. PerkinElmer, Inc.
  • 15.5. Abcam plc
  • 15.6. New England Biolabs, Inc.
  • 15.7. Takara Bio USA Inc.
  • 15.8. Lexogen GmbH
  • 15.9. Norgen Biotek Corp.
  • 15.10. Maravai LifeSciences Holdings, Inc

16. Strategic Recommendations

17. About Us & Disclaimer